FDA.reportPublic FDA data

daridorexant 25 MG Oral Tablet

RxCUI
2591502
RxNorm name
daridorexant 25 MG Oral Tablet
Display name
daridorexant 25 MG Oral Tablet
Full name
daridorexant 25 MG Oral Tablet
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:38:54

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
QUVIVIQDARIDOREXANTIdorsia Pharmaceuticals Ltd3a2d1503-b816-40c9-9fac-7e03c5a3bcef2026-02-26Warnings, Adverse reactionsExact identifier
rxcui: 2591502

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
3a2d1503-b816-40c9-9fac-7e03c5a3bcefdaridorexant 25 MG Oral Tablet [PSN] · daridorexant 25 MG Oral Tablet [SCD] · daridorexant 25 MG (as daridorexant hydrochloride 27 MG) Oral Tablet [SY]313These highlights do not include all the information needed to use QUVIVIQ safely and effectively. See full prescribing information for QUVIVIQ. QUVIVIQ (daridorexant) tablets, for oral use, CIV Initial U.S. Approval: 202220260226